LIMA1: A Newly Identified Player in the Field of Cholesterol Control

Correspondingly, lowering cholesterol leads to a proportional lowering ofrisk in randomized control trials. [...]a key objective of CVD risk mitigation is lipid lowering-and the lower, the better. Treatment ofLIMA1 knockout mice with ezetimibe, which targets NPC1L1, causes a further reduction in cho...

Full description

Saved in:
Bibliographic Details
Published inClinical chemistry (Baltimore, Md.) Vol. 64; no. 12; pp. 1792 - 1793
Main Author Donato, Leslie J
Format Journal Article
LanguageEnglish
Published England Oxford University Press 01.12.2018
Subjects
Absorption
Animals
Anticholesteremic Agents - pharmacology
Bile
Biological activity
Cholesterol
Cholesterol, LDL - blood
Cholesterol, LDL - metabolism
Cytoskeletal Proteins - antagonists & inhibitors
Cytoskeletal Proteins - genetics
Homeostasis
Humans
Hypercholesterolemia - genetics
Hypercholesterolemia - metabolism
Hypercholesterolemia - prevention & control
Intestinal Absorption - drug effects
Lipids
Mice, Knockout
Risk reduction
Online AccessGet full text

Cover

More Information
Summary:Correspondingly, lowering cholesterol leads to a proportional lowering ofrisk in randomized control trials. [...]a key objective of CVD risk mitigation is lipid lowering-and the lower, the better. Treatment ofLIMA1 knockout mice with ezetimibe, which targets NPC1L1, causes a further reduction in cholesterol absorption. [...]LIMA1 could be a novel target for cholesterol-lowering strategies. Any time a new mediator of an important biological process is revealed, it is meritorious; the discovery of LIMA1 adds meaningful and valuable mechanistic insights to the biology of cholesterol absorption. [...]it adds another puzzle piece toward elucidating the mechanisms that control cholesterol homeostasis.
Bibliography:SourceType-Other Sources-1
ObjectType-News-1
content type line 66
ISSN:0009-9147
1530-8561
DOI:10.1373/clinchem.2018.294645